Apotex Health, described as Canada’s largest drug manufacturer, is increasing the size of its upcoming initial public offering to $1.3 billion, according to reports citing a source. The company initially planned to raise about $1 billion, but it adjusts the offering upward in response to strong investor demand. The shares are reported to be priced at $24 each. The outlets present the IPO update as a change from the company’s original target, reflecting improved conditions during the sales process. While details about the number of shares, allotment, or the timing of trading are not provided in the excerpts, both reports align on the key terms of the revised offering: the increased gross proceeds target and the reported share price. The information is reported as coming from a source, and the excerpts do not indicate whether regulators have approved the updated terms or whether additional changes are expected.